Literature DB >> 9125564

Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis.

A C Savoy1, D M Lupan, P B Manalo, J S Roberts, A M Schlageter, L C Weinhold, T R Kozel.   

Abstract

Passive immunization with monoclonal antibodies (MAbs) specific for the major capsular polysaccharide of Cryptococcus neoformans alters the course of murine cryptococcosis. During studies of passive immunization for treatment of murine cryptococcosis, we noted the occurrence of an acute, lethal toxicity. Toxicity was characterized by scratching, lethargy, respiratory distress, collapse, and death within 20 to 60 min after injection of antibody. The toxic effect was observed only in mice with a cryptococcal infection and was reduced or absent in the early and late stages of disease. The clinical course and histopathology were consistent with those for shock. There was considerable variation between mouse strains in susceptibility to toxicity. Swiss Webster mice from the Charles River colony were most susceptible, followed by C3H/He, BALB/c, and C57BL/6 mice. DBA/2 mice and Swiss Webster mice from the Simonsen colony were resistant. Acute toxicity was mimicked by injection of preformed complexes of MAb and purified polysaccharide. The toxic effect was also produced by injection of MAbs into mice that were preloaded with polysaccharide. The toxic effect was not blocked by treatment of mice with chloropheniramine or anti-tumor necrosis factor alpha antibodies or by depletion of complement components via pretreatment with cobra venom factor. Toxicity was reduced by treatment of mice with high doses of epinephrine, dexamethasone, or chlorpromazine. Finally, the toxic effect was completely blocked by treatment of mice with the platelet-activating factor antagonist WEB 2170 BS or by pretreatment of mice with the liposome-encapsulated drug dichloromethylene diphosphonate, a procedure which depletes macrophages from the spleen and liver.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125564      PMCID: PMC175220          DOI: 10.1128/iai.65.5.1800-1807.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  60 in total

1.  Use of WEB 2086 and WEB 2170 as platelet-activating factor antagonists.

Authors:  J Casals-Stenzel; H O Heuer
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

2.  Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes.

Authors:  A Vecchiarelli; C Retini; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

4.  Identification of binding sites for SR 46349B, a 5-hydroxytryptamine2 receptor antagonist, in rodent brain.

Authors:  M Rinaldi-Carmona; C Congy; P Pointeau; H Vidal; J C Brelière; G Le Fur
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

5.  Cryptococcus neoformans. II. Phagocytosis by human leukocytes.

Authors:  G S Bulmer; M D Sans
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

Review 6.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.

Authors:  N Van Rooijen; A Sanders
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

7.  Immune complexes increase nitric oxide production by interferon-gamma- stimulated murine macrophage-like J774.16 cells.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  J Leukoc Biol       Date:  1995-04       Impact factor: 4.962

8.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

9.  Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes.

Authors:  A Vecchiarelli; C Retini; D Pietrella; C Monari; C Tascini; T Beccari; T R Kozel
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock.

Authors:  M Gadina; R Bertini; M Mengozzi; M Zandalasini; A Mantovani; P Ghezzi
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

View more
  15 in total

1.  Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.

Authors:  T C MacGill; R S MacGill; T R Kozel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 2.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

6.  Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

Authors:  Robert A Larsen; Peter G Pappas; John Perfect; Judith A Aberg; Arturo Casadevall; Gretchen A Cloud; Robert James; Scott Filler; William E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 7.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

8.  Do kinetics of the humoral response to Cryptococcus neoformans proteins during murine cryptococcosis reflect outcome?

Authors:  S Neuville; O Lortholary; F Dromer
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

9.  Murine IgG1 and IgG3 isotype switch variants promote phagocytosis of Cryptococcus neoformans through different receptors.

Authors:  Carolyn A Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

10.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.